🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

China health app starts online sales of Pfizer's Paxlovid for COVID treatment

Published 12/13/2022, 04:30 PM
Updated 12/14/2022, 12:46 PM
© Reuters. FILE PHOTO: Paxlovid, Pfizer's anti-viral medication to treat the coronavirus disease (COVID-19), is displayed in this picture illustration taken October 7, 2022. REUTERS/Wolfgang Rattay/Illustration
USD/CNY
-
PFE
-

(Corrects to reflect Huahai deal was in August not April in paragraph 12)

BEIJING (Reuters) - A Chinese healthcare platform has started selling Pfizer (NYSE:PFE)'s oral COVID-19 treatment Paxlovid in what appears to be the first retail sale of the drug in the country, as China braces for a surge in COVID patients.

The medication sold out just over half an hour after the listing was reported in the media, the platform's customer service said, underscoring surging demand for COVID and flu medicines in China.

Three years into the pandemic, China began pivoting away from its signature "zero COVID" policy just this month after historic protests against the economically-damaging curbs that had been championed by President Xi Jinping.

The sudden loosening of restrictions has sparked long queues outside fever clinics in a worrying sign that a wave of infections is building, even though official tallies of new COVID cases have trended lower recently as authorities eased back on testing.

Healthcare company 111.inc started selling Paxlovid for 2,980 yuan ($426.80) per box, the sales page on the app showed on Tuesday.

People can purchase the medication on the app if they submit a positive COVID-19 test result.

It was not clear how many boxes were sold or when sales would resume, or whether other retailers have also started selling the two-drug treatment.

Pfizer in an emailed statement said it is "actively collaborating with all stakeholders to secure an adequate supply of Paxlovid in China and remains committed to fulfilling the COVID-19 treatment needs of patients in China."

The launch of retail sales of Paxlovid in China could be a major earnings boost to Pfizer, which has faced some investor concerns about a sharp hit to its revenue from an expected decline in COVID vaccine demand.

Paxlovid, which was approved by China in February, has been available through hospitals to treat high-risk patients in several provinces, Chinese media Yicai reported in March.

Pfizer's clinical trial tested Paxlovid in unvaccinated people at risk for serious disease. It found that the pills taken for five days soon after symptoms onset cut the risk of hospitalization and death by 90%. It has not shown that the treatment is effective in those considered at standard risk, including vaccinated patients.

Pfizer signed a deal in August for Chinese drugmaker Zhejiang Huahai to produce Paxlovid in mainland China solely for patients there.

The U.S. drugmaker said last year that it could produce up to 120 million courses of Paxlovid this year, but it is not immediately known how many it has produced so far.

In the United States, Pfizer has delivered more than 9 million courses and patients have used over 6 million courses of the treatment, according to government data.

© Reuters. FILE PHOTO: Paxlovid, Pfizer's anti-viral medication to treat the coronavirus disease (COVID-19), is displayed in this picture illustration taken October 7, 2022. REUTERS/Wolfgang Rattay/Illustration

Pfizer's COVID-19 vaccine, jointly developed with German partner BioNTech using mRNA technology, is not approved for use in China.

(This story has been corrected to reflect Huahai deal was in August not April in paragraph 12)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.